You are here

AusPAR: Insulin aspart (rys)

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

2 September 2020
AusPAR Details
AusPAR
Active Ingredient
Insulin aspart (rys)
Product Name
Fiasp; Fiasp Penfill; and Fiasp FlexTouch
Sponsor
Novo Nordisk Pharmaceuticals Pty Ltd
Submission Number
PM-2018-05745-1-5
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
27 August 2020
Publication Date

2 September 2020